Basal cell carcinoma - Kansinòm Selil Bazal
☆ AI Dermatology — Free Service
Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
Lezyon ulsè ki afekte po nen an nan moun ki aje souvan dyagnostike kòm Kansinòm Selil Bazal (Basal cell carcinoma). Nen an se yon kote komen pou ensidan kalite kansè po sa a.
Kansinòm Selil Bazal (Basal cell carcinoma) ka prezante ak fwontyè iregilye epi li ka gen ilsè.
Kansè Selil Bazal (Basal cell carcinoma) ka konfonn ak lòt maladi.
relevance score : -100.0%
ReferencesBasal cell carcinoma (BCC) se kalite kansè po ki pi komen an. Ekspozisyon a limyè solèy la se kòz prensipal la. Prèske tout ka BCC yo montre yon siyal Hedgehog ki twò fò nan analiz molekilè a. Gen diferan tretman ki disponib, epi yo chwazi selon risk repete, enpòtans pou prezèvasyon tisi, preferans pasyan yo, ak limit maladi a.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinomas se kalite kansè po ki pi komen lakay granmoun ki gen laj 50 an oswa plis. Nimewo yo ap ogmante atravè lemond, sitou akòz ekspoze a limyè solèy la. Sèten kondisyon jenetik ka fè moun ki gen tandans devlope kansè sa a pi bonè. Basal cell carcinomas varye selon severite: yo ka soti kòm blesi supèrfisyèl oswa nodulè ki fasil pou trete, oswa kòm blesi ki pi gwo ki mande konsiltasyon ak ekip medikal espesyalize. Pwognoz depann de risk pou kansè a retounen oswa kapasite li pou domaje tisi ki toupre. Operasyon se tretman estanda pou pifò ka yo, asire retire egzak ak risk ki ba pou rekirans. Metòd ki mwens envasiv ka trete efektivman blesi supèrfisyèl.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Tretman prensipal pou BCC se operasyon. Pou BCC ki gen gwo risk oswa ki repete, espesyalman nan zòn kritik yo, yo rekòmande operasyon mikwografik kontwole. Pasyan ki gen BCC supèrfisyèl ki gen anpil risk ta ka konsidere tretman aktualite oswa metòd destriktif. Terapi fotodinamik travay byen pou BCC nodulè supèrfisyèl ki ba risk. Pou BCC ki lokalman avanse oswa metastatik, yo rekòmande inhibiteurs Hedgehog (vismodegib, sonidegib). Si gen pwogresyon maladi oswa entolerans ak inibitè Hedgehog, yo ka konsidere imunoterapi ak anti-PD1 antibody (cemiplimab). Radyoterapi se yon bon opsyon pou pasyan ki pa ka fè operasyon, espesyalman pasyan ki pi gran yo. Elektwochimyoterapi ta ka konsidere si operasyon oswa radyoterapi pa disponib.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
Faktè risk yo enkli ekspoze a limyè iltravyolèt, terapi radyasyon, ekspoze alontèm nan asenik, ak fonksyon sistèm iminitè ki pòv (egzanp transplantasyon ògàn). Ekspozisyon nan limyè UV pandan anfans se patikilyèman danjere.
Apre dyagnostik pa byopsi, tretman an se souvan retire chirijikal. Sa a ka fèt pa eksizyon senp si kansè a piti; si li pa piti, operasyon Mohs anjeneral rekòmande.
Kansè selil bazal reprezante omwen 32% nan tout kansè sou mond lan. Nan kansè po ki pa melanom, apeprè 80% se kansè selil fondamantal. Ozetazini, apeprè 35% nan gason blan ak 25% nan fi blan yo afekte pa kansè selil fondamantal nan kèk pwen nan lavi yo.
○ Dyagnostik ak Tretman
#Dermoscopy
#Skin biopsy
#Mohs surgery